Clinical Trial: Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07859592) titled 'Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma' on Sept. 30.

Brief Summary: This phase 2 trial tests the safety and effectiveness of a cancer vaccine called LabVax 3(22)-23 and GM-CSF in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced stage). LabVax 3(22)-23 is designed to target a specific antigen (labyrinthin), which is a protein found on the surface of adenocarcinoma tumor cells. Labyrinthin is a protein that is not expressed on normal cells in the skin, lungs, salivary glands, pancreas, nor other tissues. In adenocarcinoma, the tumor cells produce too m...